Vico Therapeutics is excited to announce a major milestone in our journey to revolutionize the treatment of severe genetic neurological disorders. We have successfully raised $129 million in our latest funding round—a robust vote of confidence from our investors in our groundbreaking approach to RNA modulating therapies. This substantial investment is set to accelerate the development of our innovative VICOMER platform, a state-of-the-art system designed to create tailor-made antisense oligonucleotides that target and modulate specific genetic defects. Initially, our focus is on spinocerebellar ataxia types 3 and 1, as well as Huntington’s disease—conditions that have long been associated with debilitating neurological decline and limited treatment options.
With the new capital infusion, Vico Therapeutics will expand its research and clinical development efforts, enabling us to move promising therapies from the lab to clinical environments more efficiently and with enhanced precision. This funding not only empowers our scientists to push the boundaries of RNA editing and modulation but also reinforces our commitment to patients around the globe who are in desperate need of novel and effective treatment modalities. Our goal is to ultimately provide hope and improved quality of life to those suffering from these devastating conditions. We invite the medical community, stakeholders, and all interested parties to learn more about our cutting-edge work and strategic vision by visiting www.vicotx.com. This is just the beginning of an exciting new chapter in our mission to transform neurological disease management through precision RNA therapy innovation.
